Drug Trial Radar · NCT01701973
Effect of DPP4 Inhibition on Growth Hormone Secretion
Last checked: Nov 20, 2026Latest source record: May 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jan 2013
Primary completion
May 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Vanderbilt UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Oct 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH) secretion in healthy lean adults by decreasing the degradation of growth hormone releasing hormone (GHRH). Aim 2: Test the hypothesis that decreased degradation of GHRH during acute DPP4 inhibition will result in an increase in endothelium-dependent vasodilation mediated by GH and independent from GLP1 (glucagon like peptide-1) in healthy lean adults. This study promises to provide novel data regarding how this increasingly used class of anti-diabetic drugs affects the pituitary GH axis and could affect blood vessel relaxation. Growth hormone levels are low in the setting of obesity and pre-diabetes. A further study may evaluate the effect of chronic DPP4 inhibitor therapy in a population of patients with obesity and pre-diabetes.
Conditions
- Obesity
Interventions
SitagliptinDrug
During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
PegvisomantDrug
During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
PlaceboDrug
During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
L-NMMADrug
During Aim 2, given during one of two study days (Group A subjects only)
Exendin 9-39Drug
During Aim 2, given during one of two study days (Group C subjects only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Aim 1: Stimulated Peak Growth Hormone LevelTime frame: Growth Hormone Level at 30 minutes (i.e. at completion of arginine infusion), 45 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes
- Aim 1: Percent Change From Baseline in Forearm Vascular ResistanceTime frame: Percent change from baseline in forearm vascular resistance at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes
- Aim 1: Percent Change From Baseline in Forearm Blood FlowTime frame: Percent change from baseline in forearm blood flow at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes.
- Aim 2: Percent Change From Baseline in Forearm Blood FlowTime frame: Percent change from baseline in forearm blood flow at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes.
- Aim 2: Percent Change From Baseline in Forearm Vascular ResistanceTime frame: Percent change from baseline in forearm vascular resistance at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.